reached out to MAIA Investor Relations, I keep you posted
Dear MAIA Biotechnology Investor Relations Team,
I am a shareholder following the company's progress closely, particularly the THIO-101 and THIO-104 programs. I appreciate the frequency of your recent updates, and I have a number of follow-up questions I was hoping you could help clarify, either directly or by pointing me to the relevant disclosures.
Full ORR / CR-PR breakdown (THIO-101 Part C)
The July 8, 2026 release reported a 90.5% disease control rate (19/21 evaluable patients). Could you clarify when a complete objective response rate, including the breakdown between complete responses, partial responses, and stable disease, will be made available? Is this data already locked internally, and if so, what is driving the timing of its release?Control arm / comparator methodology
Since Part C is a single-arm cohort, how is the company addressing comparability to a contemporary, checkpoint-inhibitor-era control population, given that the historical 5.8-month OS benchmark (Girard et al., 2009) predates immunotherapy? Is there a plan to present efficacy against a more contemporary comparator (e.g., Freeman et al., 2020) alongside future data releases?2L vs. 3L survival data
Earlier THIO-101 data (Parts A/B) showed lower median OS in second-line patients (~10.8 months) than in third-line patients (~17.8 months). Could you help explain the biological or methodological basis for this inversion, and whether it affects how the company is designing THIO-104's patient selection criteria?Accelerated Approval timeline
Given that the original 2026 filing guidance was issued in the January 2025 shareholder letter, is a 2026 Accelerated Approval submission still considered achievable? What specific milestones (e.g., FDA Type B/C meeting, locked dataset) remain outstanding before a filing decision can be made?Capital position and financing plan
The Q2 2026 10-Q disclosed cash of approximately $27.6 million as of June 30, 2026, alongside termination of the ATM facility effective May 21, 2026, and references to subsequent equity issuances around July 1 and August 10, 2026. Could you provide an updated, consolidated view of current cash runway, outstanding warrant overhang (13,086,220 warrants noted in the filing), and the company's plan for funding both THIO-104 completion and any potential NDA-related costs?Business development / partnership status
Given the existing clinical collaboration with Regeneron (cemiplimab) and prior reference to a master agreement with Roche, are there active business development discussions regarding a licensing or co-development partnership for ateganosine? If so, can you share what data package or milestones a partner would typically require before such a deal could be finalized?THIO-104 enrollment pace
Could you confirm current enrollment status against the stated goal of 100 patients dosed by year-end 2026, and whether the pace to date supports an interim analysis in H2 2027 as previously guided?
I would appreciate any clarification you can provide on the above, whether through direct response, a future corporate update, or reference to existing public disclosures I may have missed. Thank you for your time.